department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Cibinqo · pharmadog

pharmadog
drugs
Cibinqo

drug

patient view →

abrocitinib

Marketedupdated 2mo ago

by $PFE PFIZER INC

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Cibinqo

generic

abrocitinib

indication

Atopic Dermatitis (Atopic Eczema)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jan 14, 2027

188 days

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (9)

Jan 14, 2036compositionUS 9035074
Jan 14, 2036compositionUS 9035074
Jan 14, 2036compositionUS 9035074
Feb 19, 2034compositionUS 9545405
Feb 19, 2034compositionUS 9545405
Feb 19, 2034compositionUS 9545405
Feb 19, 2034method-of-use (U-3195)US 9549929
Feb 19, 2034method-of-use (U-3195)US 9549929
Feb 19, 2034method-of-use (U-3195)US 9549929

FDA exclusivities (6)

Jan 14, 2027NCENew Chemical Entity (5y)188d
Jan 14, 2027NCENew Chemical Entity (5y)188d
Jan 14, 2027NCENew Chemical Entity (5y)188d
Feb 9, 2026NPPNew Product (3y)
Feb 9, 2026NPPNew Product (3y)
Feb 9, 2026NPPNew Product (3y)

Data sources

ClinicalTrials.gov

last refreshed 29m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying abrocitinib

phase2Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)active not recruitingn=78
phase3A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczemarecruitingn=150
—Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.recruitingn=150
phase2Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVIDactive not recruitingn=46
phase3A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczemarecruitingn=500
—A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.active not recruitingn=1,128
phase3Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitiscompletedn=3,166
—A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitisrecruitingn=1,100

more trials →